Health Canada Approves Keytruda for PD-L1+ Head & Neck Cancer as Neoadjuvant and Adjuvant Therapy
ReutersAug 13, 2025 11:03 AM
Aug 13 (Reuters) - Merck & Co Inc MRK.N:
HEALTH CANADA APPROVES KEYTRUDA® FOR PATIENTS WITH RESECTABLE LOCALLY ADVANCED HEAD & NECK SQUAMOUS CELL CARCINOMA TUMOURS THAT ARE PD-L1 (CPS) POSITIVE AS NEOADJUVANT TREATMENT, CONTINUED AS ADJUVANT TREATMENT COMBINED WITH RADIOTHERAPY WITH OR WITHOUT CISPLATIN THEN AS MONOTHERAPY
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
U.S. Stock Market Risk Assessment: Learning from History, Mid-Term Outlook Remains Secure
We argue that the Federal Reserve’s monetary policy is the most critical factor influencing the stock market.TradingKey
19 hours ago
Don't Miss Walmart's Aug 21 Earnings: $0.73 EPS Forecast, Grocery + E-Com Dual Engines – Unlimited Upside Potential?
TradingKey - Walmart's stock price has shown an overall fluctuating upward trend since the release of its first-quarter earnings report, benefiting from investors' favoritism towards Walmart as a defensive stock, as well as expectations for its stable growth in e-commerce and grocery businesses.TradingKey
23 hours ago
Powell's Jackson Hole Speech: For U.S. Stocks, Hawk or Dove Signal Could Be a Lose-Lose?
TradingKey - As U.S. inflation and labor market data show signs of rebalancing, Treasury traders and Wall Street banks have largely priced in a rate cut at the September FOMC meeting — the first of 2025. Yet both a more dovish-than-expected tone and a potential surprise hawkish signal from Fed ChairTradingKey
23 hours ago
Eurozone Q2 GDP Commentary: Will the Euro's Upward Momentum Persist?
TradingKey - On 14 August 2025, Eurostat published Q2 GDP figures, revealing a drop in the Eurozone's quarter-on-quarter growth from 0.6% in the first quarter to 0.1%. Consequently, annual growth eased from 1.5% to 1.4%. The slowdown primarily stems from the diminishing boost from European...TradingKey
Mon, Aug 18
Bridgewater Associates Q2 2025 13F Analysis: Founder Ray Dalio’s Final Act
TradingKey - Bridgewater Associates, the world’s largest hedge fund and renowned for its macroeconomic analysis, continues to command market respect with its “risk parity” strategy and precise economic cycle timing.TradingKey
Thu, Aug 14
